NCT05256225 2026-03-18
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
4 trialsNCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT00972205 2012-07-19
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT00001383 2008-03-04
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
National Institutes of Health Clinical Center (CC)
Phase 1 Completed